Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is recommended as an option for use within NHS Wales for the symptomatic treatment of focal spasticity of upper limbs in paediatric cerebral palsy patients, two years of age or older. |
|||
|
|||
Medicine details |
|||
| Medicine name | clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) | ||
| Formulation | 500 units powder for solution for injection, 300 units powder for solution for injection | ||
| Reference number | 2626 | ||
| Indication | Symptomatic treatment of focal spasticity of upper limbs in paediatric cerebral palsy patients, two years of age or older |
||
| Company | Ipsen Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0222 | ||
| NMG meeting date | 05/01/2022 | ||
| AWMSG meeting date | 09/02/2022 | ||
| Date of issue | 23/02/2022 | ||